Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: A multicenter, randomized, controlled, open-label, parallel-group, clinical trial

Journal of Sexual Medicine

Volumn 10, Issue 6, 2013, Pages 1575-1584

  Chen, Junya ^a   Geng, Li ^a   Song, Xuehong ^b   Li, Hongxia ^c   Giordan, Nicola ^d   Liao, Qinping ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Fidia Advanced Biopolymers   (Italy)

Author keywords

Estriol Cream; Hyaluronic Acid Vaginal Gel; Menopause; Vaginal Dryness

Indexed keywords

ESTRIOL; HYALOFEMME; HYALURONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BURNING SENSATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ECHOGRAPHY; ENDOMETRIAL THICKNESS; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VAGINA CANDIDIASIS; VAGINA FLORA; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS; VISUAL ANALOG SCALE;

EID: 84878711961     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12125     Document Type: Article

References (35)

1. Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
2. Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509-522.
3. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87-94.
4. Sobel JD. Bacterial vaginosis. Annu Rev Med 2000;51:349-356.
5. Matovina M, Husnjka K, Milutin N, Ciglar Srecko GM. Possible role of bacterial and viral infections in miscarriages. Fertil Steril 2004;81:662-669.
6. Murta EFC, Filho ACA, Barcelos ACM. Relation between vaginal and endocervical pH in pre- and post-menopausal women. Arch Gynecol Obstet 2005;272:211-213.
7. Brabin L, Roberts SA, Fairbrother E, Mandal D, Higgins SP, Chandiok S, Wood P, Barnard G, Kitchener HC. Factors affecting vaginal pH levels among female adolescents attending genitourinary medicine clinics. Sex Transm Infect 2005;81:483-487.
8. Cardozo L, Bachmann G, McClish D, Fonda D, Birgerson L. Meta-analysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: Second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998;92:722-727.
9. Pandit L, Ouslander JG. Postmenopausal vaginal atrophy and atrophic vaginitis. Am J Med Sci 1997;314:228-231.
10. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005;52:S46-52.
11. Krychman ML. Vaginal estrogens for the treatment of dyspareunia. J Sex Med 2011;8:666-674.
12. Beral V, Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
13. Summary of Product Characteristics RA 1740 NL S4 (REF 3.0) English OVESTIN vaginal cream, 1mg/g. 2009.
14. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women (Review). Cochrane Database Syst Rev 2006;4:1-91.
15. Griesser H, Skonietzki S, Fischer T, Fielder K, Suesskind M. Low dose estriol pessaries for the treatment of vaginal atrophy: A double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas 2012;71:360-368.
16. Cano A, Estévez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL, Castellanos E, Moral E, Nieto C, Del Prado JM, Ferrer J. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: Results from a pivotal phase III study. Menopause 2012;19:1130-1139.
17. Mazur D, Vens-Cappell B, Lohmann K, Breckwoldt M. Fractionated use of a 17b estradiol cream for the treatment of vaginal atrophy in postmenopausal women. Geburtshilfe Frauenheilkd 2005;65:584-589.
18. Eriksen PS, Rasmussen H. Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: A double-blind placebo controlled study. Eur J Obstet Gynecol Reprod Biol 1992;44:137-144.
19. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency-A pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-127.
20. Xiao BB, Liu ZH, Liao QP. Microecological investigation of vaginal microflora in women with varying degree gynecologic symptoms in clinics. [Article in Chinese. Zhonghua Fu Chan Ke Za Zhi 2009;44:6-8.
21. Heinemann C, Reid G. Vaginal microbial diversity among postmenopausal women with and without hormone replacement therapy. Can J Microbiol 2005;51:777-781.
22. Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194-203.
23. Franchi LM, Kicovic PM. A group-comparative study of effects of Ovestin cream in post-menopausal women with vaginal atrophy. Maturitas 1980;2:311-319.
24. Morali G, Polatti F, Metelitsa EN. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Drug Res 2006;56:230-238.
25. Kicovic PM, Cortesprieto J, Milojevic S, Haspels AA, Aljinovic A. The treatment of post-menopausal vaginal atrophy with Ovestin vaginal cream or suppositories: Clinical, endocrinological, safety aspects. Maturitas 1980;2:275-282.
26. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996;23:259-263.
27. Le Donne M, Caruso C, Mancuso A, Costa G, Iemmo R, Pizzimenti G, Cavallari V. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Arch Gynecol Obstet 2011;283:1319-1323.
28. Rioux J, Devlin C, Gelfand M, Steinberg W, Hepburn D. 17B estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000;7:156-161.
29. Carter J, Goldfrank D, Schover LR. Simple strategies for vaginal health promotion in cancer survivors. J Sex Med 2011;8:549-559.
30. Anderson I. The properties of hyaluronan and its role in wound healing. Prof Nurse 2001;17:232-235.
31. Gerdin B, Hallgren R. Dynamic role of hyaluronan (HYA) in connective tissue activation and inflammation. J Intern Med 1997;242:49-55.
32. Weigel PH, Fuller GM, LeBoeuf RD. A model for the role of hyaluronic acid and fibrin in the early events during the inflammatory response and wound healing. J Theor Biol 1986;119:219-234.
33. Oksala O, Salo T, Tammi R, Häkkinen L, Jalkanen M, Inki P, Larjava H. Expression of proteoglycans and hyaluronan during wound healing. J Histochem Cytochem 1995;43:125-135.
34. Ekin M, Yaşar L, Savan K, Temur M, Uhri M, Gencer I, Ki{dotless}vanç E. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Arch Gynecol Obstet 2011;283:539-543.
35. Karaosmanoglu O, Cogendez E, Sozen H, Asoglu MR, Akdemir Y, Eren S. Hyaluronic acid in the treatment of postmenopausal women with atrophic vaginitis. Int J Gynaecol Obstet 2011;113:156-157.